Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Future Oncol ; 16(20): 1425-1432, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-260506

ABSTRACT

Background: We describe cancer patients with coronavirus disease-2019 (COVID-19) infection treated at the Piacenza's general hospital (north Italy). Materials & methods: 25 cancer patients infected by COVID-19 admitted at the Piacenza's general hospital from 21 February to 18 March 2020. Outcome from the infection were compared with infected noncancer patients. Results: 20 patients (80%) were treated with antiviral therapy and hydroxychloroquine and five (20%) received hydroxychloroquine alone. Nine (36%) patients died, while 16 (64%) overcome the infection. In the control group the mortality was 16.13% and the overcome from infection was 83.87%. Conclusion: Mortality for COVID-19 was greater in cancer patients when compared with noncancer patients, worse prognosis for older age, women and patients treated with hydroxychloroquine alone. However, the comparisons did not reach statistical significance in most cases. This could be due to the small sample size that is the main limitation of the study.


Subject(s)
Antiviral Agents/therapeutic use , Coronavirus Infections/drug therapy , Coronavirus Infections/mortality , Hydroxychloroquine/therapeutic use , Neoplasms/mortality , Pneumonia, Viral/drug therapy , Pneumonia, Viral/mortality , Age Factors , Aged , Aged, 80 and over , Azithromycin/therapeutic use , Betacoronavirus , COVID-19 , Ceftriaxone/therapeutic use , Cobicistat/therapeutic use , Darunavir/therapeutic use , Drug Therapy, Combination , Female , HIV Protease Inhibitors/therapeutic use , Humans , Italy , Lopinavir/therapeutic use , Male , Methylprednisolone/therapeutic use , Middle Aged , Neoplasms/drug therapy , Pandemics , Ritonavir/therapeutic use , SARS-CoV-2 , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL